Physician profile
Christopher Ryan Jimenez
NPI 1841794302
$564.03
in general payments reported to CMS, 2019-2025
8 companies · $120 in 2025
The $120 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.20 · 2022: $76.57 · 2023: $33.98 · 2024: $323 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $286.23 | 2024-2025 | Ingrezza |
| Corium, LLC | $137.75 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $37.66 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $31.54 | 2022 | |
| Neos Therapeutics, LP | $25.15 | 2021-2022 | |
| Pfizer INC. | $17.56 | 2022 | |
| Glaxosmithkline, LLC. | $14.62 | 2025 | Pediarix, Bexsero, Flulaval Quadrivalent |
| Sobi, INC | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.